IMCC Stock Analysis: Buy, Sell, or Hold?
IMCC - IM Cannabis Corp. Common Shares
$1.75
0.00 (0.00%)
▲
5d:
-20.45%
30d:
+1246.15%
90d:
+607.64%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When IMCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IMCC is down 20.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IMCC is down 20.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMCC is currently trading at $1.75, which is considered slightly high relative to its 30-day fair value range of $-0.17 to $2.38.
Technical Outlook: Technically, IMCC is in a uptrend. The price is currently testing key support at $1.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IMCC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.22 (+369.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMCC is in a uptrend. The price is currently testing key support at $1.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IMCC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.22 (+369.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$-0.17 -
$2.38
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 369.8% below Wall St target ($8.22)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.17 -
$2.38
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.73
Resistance Level
$3.90
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.37
Wall Street Target
$8.22
(+369.8%)
Revenue Growth (YoY)
-40.2%
Profit Margin
-39.1%
Share & Embed Analysis
Last updated: September 13, 2026 10:49 PM ET
Data refreshes hourly during market hours. Next update: 11:49 PM
Data refreshes hourly during market hours. Next update: 11:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
